Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P615: The unfinished symphony: golimumab is efficient in patients with refractory Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Greener T., Greenberg G., Steinhart H., Silverberg M.

Mount Sinai Hospital, Department of Gastroenterology, Toronto, Canada

P616: Natural history and phenotype of inflammatory bowel disease with co-existent celiac diseaseECCO '17 Barcelona
Year: 2017
Authors:

Tse C.S.*1, Deepak P.2, De La Fuente J.1, Murray J.2, Papadakis K.2

1Mayo Clinic, Internal Medicine, Rochester, United States 2Mayo Clinic, Gastroenterology, Rochester, United States

P617: Extraintestinal autoimmune phenomena during treatment with vedolizumabECCO '17 Barcelona
Year: 2017
Authors:

Lissner D.*1, Sonnenberg E.1, Glauben R.1, Allers C.1, Preiss J.1, Schneider T.1, Loddenkemper C.2, Siegmund B.1

1Charité - Campus Benjamin Franklin, Gastroenterology, Berlin, Germany 2PathoTres Practice for Pathology, Berlin, Germany

P618: Rapidity of onset of response to adalimumab in luminal Crohn's disease. Data from RAPIDA trialECCO '17 Barcelona
Year: 2017
Authors:

Marin-Jimenez I.*1, Casellas F.2, Esteve M.3, Castro-Laria L.4, García-Lόpez S.5, Ceballos D.6, Echarri A.7, Martín-Arranz M.D.8, Busquets D.9, Llaό J.10, Navarro-Llavat M.11, Huguet J.M.12, Argüelles-Arias F.4, Vicente R.5, Rodriguez-San Pedro L.13, Diaz G.14, Casado R.14, Barreiro-de Acosta M.15

1Hospital Universitario Gregorio Marañόn, Instituto de Investigaciόn Sanitaria Gregorio Marañόn (IiSGM), Madrid, Spain 2Hospital Universitario Vall d'Hebrόn, Gastroenterology, Barcelona, Spain 3Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain 4Hospitales Universitarios Virgen Macarena-Rocío, Sevilla, Spain 5Hospital Universitario Miguel Servet, Zaragoza, Spain 6Dr. Negrin University Hospital, Las Palmas de Gran Canaria, Spain 7Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain 8Hospital Universitario La paz, Madrid, Spain 9Hospital Universitari Dr. Josep Trueta, Girona, Spain 10Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain 11Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain 12Hospital General Universitario de Valencia, Valencia, Spain 13AbbVie Spain, Madrid, Spain 14AbbVie Farmacéutica S.L.U., Inmunology, Madrid, Spain 15Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain

P619: Tofacitinib for the treatment of resistant ulcerative colitis: the University of Chicago experienceECCO '17 Barcelona
Year: 2017
Authors:

Weisshof R., Aharoni Golan M., Masching A., Rubin D.T.

University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States

P620: Network meta-analysis of efficacy and safety of different intravenous iron compounds for the treatment of iron deficiency anaemia in patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Aksan A.*1,2, Işık H.3, Radeke H.H.2,4, Dignass A.2,5, Stein J.2,6

1Hacettepe University, Faculty of Health Sciences, Ankara, Turkey 2Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany 3Hacettepe University, Faculty of Sciences, Ankara, Turkey 4Pharmazentrum Frankfurt, Clinic of the Goethe University, Institute of Pharmacology and Toxicology, Frankfurt/Main, Germany 5Agaplesion Markus Krankenhaus, Department of Gastroenterology, Frankfurt/Main, Germany 6DGD Clinics Sachsenhausen, Frankfurt/Main, Germany

P621: Efficacy and safety of golimumab in ulcerative colitis. Preliminary data from a multicenter Italian studyECCO '17 Barcelona
Year: 2017
Authors:

Bossa F.*1, Valvano M.R.1, Costantino G.2, Vinci E.3, Rispo A.4, Mendolaro M.5, Patturelli M.6, Shaini E.7, Mazzuoli S.8, RIcciardelli C.9, Tursi A.10, Lauria A.11, Paese P.12, Azzarone A.13, Sebkova L.14, Pranzo G.15, Fries W.2, Castiglione F.4, Cappello M.5, Privitera A.3, Principi B.7, Andriulli A.1

1IRCCS Casa Sollievo della Sofferenza, Gastroenterology, San Giovanni Rotondo, Italy 2University of Messina, Clinical and experimental Medicine, Messina, Italy 3Ospedale Cannizzaro, Chirurgia, Catania, Italy 4Federico II univertity, Gastroenterology, Naples, Italy 5University of Palermo, Gastroenterology, Palermo, Italy 6Second University of Naples, Gastroenterology, Naples, Italy 7University of Bari, Gastroenterology, Bari, Italy 8Ospedale San Nicola Pellegrino, Gastroenterology, Trani, Italy 9Ospedale di poggiardo, Gastroenterology, Poggiardo, Italy 10ASL BAT, Gastroenterology, Andria, Italy 11Bianchi Melacrino Borreli Hospital, Gastroenterology, Reggio Calabria, Italy 12Ospedale Annunziata, Gastroenterology, Cosenza, Italy 13San Paolo Hospital, Gastroenterology, Bari, Italy 14Pugliese Ciaccio Hospital, Gastroenterology, Catanzaro, Italy 15Calle D'Itria Hospital, Surgery, Martina Franca, Italy

P622: Efficacy of probiotics in inflammatory bowel disease: systematic review and meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Derwa Y.1, Gracie D.J.*1,2, Hamlin P.J.1, Ford A.C.1,2

1St. James's University Hospital, Leeds Gastroenterology Institute, Leeds, United Kingdom 2University of Leeds, LIBACS, Leeds, United Kingdom

P623: Therapeutic preferences and outcomes in newly diagnosed patient with inflammatory bowel diseases in the biological era in Hungary. A nationwide study based on the National Health Insurance Fund databaseECCO '17 Barcelona
Year: 2017
Authors:

Gonczi L.*1, Vegh Z.1, Kurti Z.1, Lovasz B.D.1, Golovics P.A.1, Fadgyas-Freyler P.2, Gimesi-Orszagh J.2, Gecse K.B.1, Lakatos P.L.1

1Semmelweis University, First Department of Medicine, Budapest, Hungary 2National Health Insurance Fund (OEP), Strategic Analysis Department, Budapest, Hungary

P624: Chromoendoscopy and narrow band imaging versus conventional white light endoscopy for detection of neoplasia in ulcerative colitis – a systematic review and meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Har-Noy O.1, Katz L.1, Avni T.2, Bessissow T.3, Young D.4, Koulaouzidis A.4, Engel T.1, Eliakim R.1, Ben-Horin S.1, Kopylov U.*5

1Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel 2Rabin Medical Center, Internal Medicine, Petach Tikva, Israel 3McGill University Health Center, Gastroenterology, Montreal, Canada 4Royal Infirmary of Edinburgh, Endoscopy Unit, Centre for Liver and Digestive Disorders, Edinburgh, United Kingdom 5Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel

P625: Ustekinumab use in Crohn's disease: effectiveness of dose escalationECCO '17 Barcelona
Year: 2017
Authors:

Greenup A., Rosenfeld G., Bressler B.

University of British Columbia, Gastroenterology, Vancouver, Canada

P626: Ustekinumab for the treatment of perianal fistulas in patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Battat R.*1,2, Bessissow T.1, Strohl M.1, Kopylov U.3, Bitton A.1, Cohen A.2, Seidman E.1, Afif W.1

1McGill University Health Centre, Department of Gastroenterology, Montreal, Canada 2Jewish General Hospital, Department of Gastroenterology, Montreal, Canada 3Sheba Medical Center Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Department of Gastroenterology, Tel Aviv, Israel

P627: Surrogate markers of mucosal healing in Crohn's disease patients in clinical remission under biological/immunomodulator treatmentECCO '17 Barcelona
Year: 2017
Authors:

Siakavellas S., Kostas A., Kosmidis C., Gizis M., Papatheodoridis G., Bamias G.

National & Kapodistrian University of Athens, Academic Dpt. of Gastroenterology, Athens, Greece

P628: Anti-TNF therapy in refractory pouchitis and Crohn's disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis: a systematic review and meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Huguet M.1, Pereira B.2, Goutte M.1,3, Goutorbe F.1,4, Allimant C.1, Reymond M.1, Bommelaer G.1,3, Buisson A.*1,3

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France 2University Hospital, Biostatistics Unit, DRCI, Clermont-Ferrand, France 3UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France 4Hospital of Bayonne, Gastroenterology Department, Bayonne, France

P629: Efficacy, safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice: results of one yearECCO '17 Barcelona
Year: 2017
Authors:

Rodríguez Glez G.E.*1, Díaz Hernández L.1, Morales Barrios J.A.2, Vela González M.1, Tardillo Marín C.A.1, Viña Romero M.M.2, Rodríguez Díaz C.Y.1, Arranz Hernández L.1, Hernández Camba A.1, Merino Alonso F.J.2, Pérez Hernández F.1

1Hospital Universitario Ntra. Sra. Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain 2Hospital Universitario Ntra. Sra. Candelaria, Pharmacology, Santa Cruz de Tenerife, Spain

P630: The long-term efficacy of adalimumab on Crohn's disease comorbid with perianal lesions and poor prognostic factor analysisECCO '17 Barcelona
Year: 2017
Authors:

Nozaki R., Goto H., Tsuji Y., Takano S., Yamada K., Takano M.

Coloproctology Center, Takano Hospital, Kumamoto, Japan

P631: Results and predictors of outcome of endoscopic balloon dilation of colonic strictures in inflammatory bowel diseasesECCO '17 Barcelona
Year: 2017
Authors:

Bibani N., Yakoubi M., Sabbah M., Trad D., Ouakaa A., Gargouri D., Elloumi H., Kharrat J.

Habib Thameur Hospital, Gastro enterology, Tunis, Tunisia

P632: Comparative analysis of the pharmacokinetics of Inflectra® biosimilar with Remicade® in the induction phase of remission in patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Juan G.*1, Mora M.2, Alvariño A.3, Maroto N.2, Ferrer I.2, Hinojosa E.2, Hinojosa M.D.2, Ferrandis P.1, Hinojosa J.2

1Hospital de Manises, Department of Pharmacy, Manises, Spain 2Hospital de Manises, IBD Unit, Manises, Spain 3Hospital de Manises, Department of Labratory, Manises, Spain

P633: Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Fiorino G.*1, Ruiz-Agüello M.B.2, Maguregui A.2, Nagore D.2, Radice S.1, Gilardi D.1, Correale C.1, Allocca M.1, Furfaro F.1, Alfieri M.1, Martínez A.2, Danese S.1,3

1Humanitas Clinical and Research Center, Department of Gastroenterology, Milan, Italy 2Progenika Biopharma SA, R&D Department, Derio, Spain 3Humanitas University, Department of Biomedical Sciences, Milan, Italy

P634: Long term risk of relapse after anti-TNF discontinuation based on mucosal healing in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

García Ortíz J.M., Sáenz Gallo M., Trigo Salado C., De La Cruz Ramirez M.D., Marquez Galan J.L., Herrera Justiniano J.M., Bozada García J.M., Leo Carnerero E.

HU Virgen del Rocío, UGC Digestive Diseases, Seville, Spain